Vimarsana
Biggest News Aggregation in the World

Page 34 - Eqs Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Eqs Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Eqs Group Today - Breaking & Trending Today

EQS-Adhoc: PolyPeptide Group AG: PolyPeptide Group gibt vollständige Ausübung der Mehrzuteilungsoption bekannt - Vimarsana News

EQS-Adhoc: PolyPeptide Group AG: PolyPeptide Group gibt vollständige Ausübung der Mehrzuteilungsoption bekannt

EQS-Adhoc: PolyPeptide Group AG: PolyPeptide Group gibt vollständige Ausübung der Mehrzuteilungsoption bekannt PolyPeptide Group gibt vollständige Ausübung der Mehrzuteilungsoption bekannt 05.05.2021 / 17:40 CET/CEST Veröffentlichung einer Ad-hoc-Mitteilung gemäss Art. 53 KR Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. FOR R...

EQS-Adhoc: HBM Healthcare Investments AG: 30.04.2021 - Vimarsana News

EQS-Adhoc: HBM Healthcare Investments AG: 30.04.2021

EQS-Adhoc: HBM Healthcare Investments AG: 30.04.2021 30.04.2021 Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. in CHF 2'089 CYTD Calendar Year to Date (since 1.1.2021) HBM Healthcare Investments AG Fax +41 41 710 75 78 E-Mail: hbm@hbmhealthcare.com Should you wish to unsubscribe from all HBM Healthcare Investments news, please unsubscribe here. Disclaimer: This message may contain confidential or privileged Information and is intended only for the use of the addressee named above. If you are not the intended...

EQS-Adhoc: IGEA Pharma N.V.: IGEA to get SIX approval to delay the 2020 annual report disclosure - Vimarsana News

EQS-Adhoc: IGEA Pharma N.V.: IGEA to get SIX approval to delay the 2020 annual report disclosure

EQS-Adhoc: IGEA Pharma N.V.: IGEA to get SIX approval to delay the 2020 annual report disclosure IGEA to get SIX approval to delay the 2020 annual report disclosure 30-Apr-2021 / 22:45 CET/CEST Release of an ad hoc announcement pursuant to Art. 18 KR The issuer is solely responsible for the content of this announcement. IGEA to get SIX approval to delay the 2020 annual report disclosure Hoofddorp, the Netherlands, 30 April 2021. IGEA Pharma N.V. (SIX: IGPH) today announced the grant of a temporary exemption from its disclosure obligations with respect to the 2020 annual report. As anticipate...

EQS-News: Nordea Bank Abp: First quarter results 2021 - Vimarsana News

EQS-News: Nordea Bank Abp: First quarter results 2021

EQS-News: Nordea Bank Abp: First quarter results 2021 Nordea Bank Abp: First quarter results 2021 29.04.2021 / 08:50 29 April 2021 at 7:30 EET Summary of the quarter: Continued growth in business volumes and customer satisfaction across Nordics. Mortgage volumes grew by 6% in local currencies, year on year, and lending to small and medium-sized enterprises increased by 7%. Assets under management increased by 33% to EUR 372bn, driven by market recovery and continued net inflows, especially into retail funds. Customer satisfaction scores continue to increase. Strong result, driven by high in...

EQS-News: PolyPeptide Group legt IPO-Angebotspreis bei CHF 64.00 pro Aktie fest und beginnt Handel an der Schweizer Börse - Vimarsana News

EQS-News: PolyPeptide Group legt IPO-Angebotspreis bei CHF 64.00 pro Aktie fest und beginnt Handel an der Schweizer Börse

EQS-News: PolyPeptide Group legt IPO-Angebotspreis bei CHF 64.00 pro Aktie fest und beginnt Handel an der Schweizer Börse PolyPeptide Group legt IPO-Angebotspreis bei CHF 64.00 pro Aktie fest und beginnt Handel an der Schweizer Börse 29.04.2021 / 07:00 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. FOR RELEASE IN SWITZERLAND - THIS IS A RESTRICTED COMMUNICATION AND YOU MUST NOT FORWARD IT OR ITS CONTENTS T...